Sava receives $36M in funding, partners with Ascensia
By HME News Staff
Updated 1:02 PM CDT, Wed October 14, 2026
LONDON – Sava Technologies has received $36 million in Series B funding, alongside an agreement appointing Ascensia, a subsidiary of PHC Holdings Corp., as its commercialization and distribution partner, starting off in Europe. Founded in 2019, Sava has developed a wearable built on its proprietary microsensor technology that measures molecules just beneath the skin, painlessly and continuously. While starting with glucose, the platform is designed to track other biomarkers, too, opening the door to continuous sensing well beyond diabetes, the company says. “For decades, continuous monitoring has been held back by the same legacy technology,” said Renato Circi, co-founder and co-CEO of Sava. “This is about to change. We’re thrilled to be partnering with Ascensia, a global powerhouse in the space, to deliver, as a first step, something radically better to millions of people with diabetes.” Ascensia’s products are sold in more than 90 countries, with direct commercial organizations in 29 markets. The company says its strong global footprint, deep market knowledge and established relationships with clinicians and payers give Sava the foundations to take its technology to market.
Comments